Biotech Industry · global
GSK Completes $10.6 Billion Acquisition of Nuvalent, Moving Targeted Lung Cancer Drugs to the Regulatory Front Line
Two drug candidates face FDA decision deadlines this year, while another HER2 lung cancer program remains in early clinical development; the deal gives GSK a near-commercial growth opportunity while also taking on uncertainties surrounding efficacy, safety, and the timeline to market.
GSK has completed its approximately $10.6 billion acquisition of Nuvalent, buying not only three lung cancer drug candidates but also a development timeline that could rapidly move into commercialization. Two lead drugs are already under review by the U.S. Food and Drug Administration (FDA). If approved, this major deal could face its first real market test as early as 2027.
According to documents Nuvalent filed with the U.S. Securities and Exchange Commission, the tender offer expired on July 14, with approximately 91.3% of outstanding shares validly tendered. The merger was completed on July 15, making Nuvalent a wholly owned subsidiary of GSK without requiring a separate shareholder vote. Shareholders received $124 in cash per share, and Nuvalent’s shares subsequently ceased trading and entered the delisting process.
At the heart of the transaction are two drug candidates targeting lung cancers with specific genetic alterations. Zidesamtinib targets ROS1, while neladalkib targets ALK, and both are under FDA review. Based on the timeline disclosed when the deal was announced, the FDA target decision dates are September 18 and November 27, 2026, respectively. This means GSK is acquiring not merely an early-stage research platform, but two assets that could receive regulatory decisions within months.
Nuvalent’s third clinical program, NVL-330, targets HER2-mutant non-small cell lung cancer and remains in a Phase 1 trial. Together with the company’s preclinical programs, it preserves a longer-term research and development horizon for the acquisition. However, compared with the two drugs already submitted for review, the immediate questions NVL-330 must answer remain its safety in humans, appropriate dosage, and preliminary antitumor activity.
GSK previously expected these assets to contribute to revenue growth beginning in 2027 and to be accretive to core earnings per share in 2029. The price of $124 per share represented a premium of approximately 40% over the closing price on the day before the deal was announced, indicating that the buyer was willing to pay a substantial price for precision-oncology assets nearing regulatory milestones. Conversely, whether the FDA grants approval, the scope of the labels, the speed of the launches, and competition from similar therapies will directly determine the acquisition’s return.
Completion of the transaction does not itself mean that the drugs have been approved, nor does it provide any new clinical efficacy or safety results. The next two FDA decision dates will break this $10.6 billion strategic bet into more concrete questions: whether the candidates can clear the regulatory hurdle, which patients they can serve, and whether GSK can turn Nuvalent’s scientific assets into products capable of supporting the acquisition price.